Showcases Stock ranks Forex

Horizon Therapeutics Public Limited Company (HZNP)
79.93  1.97 (2.53%) 09-18 16:00
Open: 79 Pre. Close: 77.96
High: 81.11 Low: 78.14
Volume: 4,139,770 Market Cap: 17,612M
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 1,175 full-time employees. The firm is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The firm markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The firm's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 81.21 - 81.511 81.511 - 81.753
Low: 77.338 - 77.712 77.712 - 78.013
Close: 79.362 - 79.946 79.946 - 80.415
Stock Technical Analysis
Target: Six months: 94.74
One year: 110.65
Support: Support1: 72.08
Support2: 66.50
Resistance: Resistance1: 81.11
Resistance2: 94.74
Pivot: 74.46
Moving Averages: MA(5): 78.25
MA(20): 74.28
MA(100): 58.58
MA(250): 42.69
MACD: MACD(12,26): 2.35
Signal(12,26,9): 2.04
%K %D: %K(14,3): 87.36
%D(3): 88.47
RSI: RSI(14): 65.52
52-Week: High: 81.18
Low: 23.81
Change(%): 191.7
Average Vol(K): 3-Month: 247362
10-Days: 237579
Price, MAs and Bollinger Bands
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.

HZNP has closed below upper band by 7.3%. Bollinger Bands are 20.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Fri, 18 Sep 2020
Is Horizon Therapeutics Public Limited (HZNP) Stock Outpacing Its Medical Peers This Year? - Nasdaq

Fri, 18 Sep 2020
Horizon Therapeutics (NASDAQ:HZNP) Upgraded to Strong-Buy at BidaskClub - MarketBeat

Wed, 16 Sep 2020
Horizon Therapeutics PLC (NASDAQ:HZNP) Expected to Announce Quarterly Sales of $517.37 Million - MarketBeat

Sat, 12 Sep 2020
Have Insiders Been Selling Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Shares This Year? - Simply Wall St

Thu, 10 Sep 2020
The Unprecedented Rise of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) - The Oracle Dispatch

Tue, 08 Sep 2020
Hedge Funds Never Been This Bullish On Horizon Therapeutics (HZNP) - Yahoo Finance

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Drug Manufacturers General
Shares Out. (M) 220.35
Shares Float (M) 203.84
% Held by Insiders 1.31
% Held by Institutions 91.66
Shares Short (K) 4080
Shares Short Prior Month (K) 4790
Stock Financials
EPS 2.550
Book Value (p.s.) 11.830
Profit Margin 34.09
Operating Margin 8.22
Return on Assets (ttm) 1.9
Return on Equity (ttm) 26.6
Qtrly Rev. Growth 44.3
Gross Profit (p.s.) 4.257
Sales Per Share 6.898
EBITDA (p.s.) 0.647
Qtrly Earnings Growth
Operating Cash Flow (M) 315.90
Levered Free Cash Flow (M) 240.31
Stock Valuation
PE Ratio 31.35
PEG Ratio
Price to Book value 6.76
Price to Sales 11.59
Price to Cash Flow 55.75
Stock Dividends
Dividend Yield
Dividend Growth

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator